Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00434133 | Lung | AIS | macromolecule glycosylation | 35/1849 | 226/18723 | 4.93e-03 | 4.27e-02 | 35 |
GO:000697923 | Lung | MIAC | response to oxidative stress | 43/967 | 446/18723 | 6.39e-05 | 3.12e-03 | 43 |
GO:007155922 | Lung | MIAC | response to transforming growth factor beta | 28/967 | 256/18723 | 1.51e-04 | 5.95e-03 | 28 |
GO:006219723 | Lung | MIAC | cellular response to chemical stress | 34/967 | 337/18723 | 1.54e-04 | 6.04e-03 | 34 |
GO:001603223 | Lung | MIAC | viral process | 39/967 | 415/18723 | 2.34e-04 | 7.89e-03 | 39 |
GO:007156022 | Lung | MIAC | cellular response to transforming growth factor beta stimulus | 26/967 | 250/18723 | 5.59e-04 | 1.42e-02 | 26 |
GO:00075853 | Lung | MIAC | respiratory gaseous exchange by respiratory system | 11/967 | 68/18723 | 6.76e-04 | 1.59e-02 | 11 |
GO:004311222 | Lung | MIAC | receptor metabolic process | 19/967 | 166/18723 | 9.61e-04 | 2.03e-02 | 19 |
GO:003459923 | Lung | MIAC | cellular response to oxidative stress | 28/967 | 288/18723 | 1.01e-03 | 2.07e-02 | 28 |
GO:000170131 | Lung | MIAC | in utero embryonic development | 33/967 | 367/18723 | 1.44e-03 | 2.54e-02 | 33 |
GO:190288222 | Lung | MIAC | regulation of response to oxidative stress | 13/967 | 98/18723 | 1.57e-03 | 2.67e-02 | 13 |
GO:000722921 | Lung | MIAC | integrin-mediated signaling pathway | 13/967 | 107/18723 | 3.46e-03 | 4.43e-02 | 13 |
GO:00160326 | Stomach | GC | viral process | 58/1159 | 415/18723 | 4.75e-09 | 5.72e-07 | 58 |
GO:00069796 | Stomach | GC | response to oxidative stress | 60/1159 | 446/18723 | 1.10e-08 | 1.01e-06 | 60 |
GO:00621976 | Stomach | GC | cellular response to chemical stress | 44/1159 | 337/18723 | 2.24e-06 | 9.73e-05 | 44 |
GO:00345996 | Stomach | GC | cellular response to oxidative stress | 38/1159 | 288/18723 | 8.45e-06 | 2.96e-04 | 38 |
GO:00059964 | Stomach | GC | monosaccharide metabolic process | 31/1159 | 257/18723 | 2.90e-04 | 4.67e-03 | 31 |
GO:19004076 | Stomach | GC | regulation of cellular response to oxidative stress | 15/1159 | 89/18723 | 3.46e-04 | 5.47e-03 | 15 |
GO:00193184 | Stomach | GC | hexose metabolic process | 29/1159 | 237/18723 | 3.53e-04 | 5.54e-03 | 29 |
GO:00160525 | Stomach | GC | carbohydrate catabolic process | 21/1159 | 154/18723 | 5.38e-04 | 7.55e-03 | 21 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00510 | Colorectum | AD | N-Glycan biosynthesis | 21/2092 | 53/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 21 |
hsa005101 | Colorectum | AD | N-Glycan biosynthesis | 21/2092 | 53/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 21 |
hsa005102 | Colorectum | MSS | N-Glycan biosynthesis | 20/1875 | 53/8465 | 7.17e-03 | 2.83e-02 | 1.73e-02 | 20 |
hsa00513 | Colorectum | MSS | Various types of N-glycan biosynthesis | 16/1875 | 42/8465 | 1.39e-02 | 4.53e-02 | 2.77e-02 | 16 |
hsa005103 | Colorectum | MSS | N-Glycan biosynthesis | 20/1875 | 53/8465 | 7.17e-03 | 2.83e-02 | 1.73e-02 | 20 |
hsa005131 | Colorectum | MSS | Various types of N-glycan biosynthesis | 16/1875 | 42/8465 | 1.39e-02 | 4.53e-02 | 2.77e-02 | 16 |
hsa05202 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
hsa052021 | Colorectum | FAP | Transcriptional misregulation in cancer | 45/1404 | 193/8465 | 9.19e-03 | 3.33e-02 | 2.03e-02 | 45 |
hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa052026 | Lung | IAC | Transcriptional misregulation in cancer | 40/1053 | 193/8465 | 6.90e-04 | 5.90e-03 | 3.92e-03 | 40 |
hsa0520211 | Lung | IAC | Transcriptional misregulation in cancer | 40/1053 | 193/8465 | 6.90e-04 | 5.90e-03 | 3.92e-03 | 40 |
hsa052022 | Lung | AIS | Transcriptional misregulation in cancer | 39/961 | 193/8465 | 2.15e-04 | 2.41e-03 | 1.54e-03 | 39 |
hsa052023 | Lung | AIS | Transcriptional misregulation in cancer | 39/961 | 193/8465 | 2.15e-04 | 2.41e-03 | 1.54e-03 | 39 |
hsa052024 | Lung | MIAC | Transcriptional misregulation in cancer | 22/507 | 193/8465 | 2.64e-03 | 2.26e-02 | 1.64e-02 | 22 |
hsa052025 | Lung | MIAC | Transcriptional misregulation in cancer | 22/507 | 193/8465 | 2.64e-03 | 2.26e-02 | 1.64e-02 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FUT8 | SNV | Missense_Mutation | | c.109N>A | p.Asp37Asn | p.D37N | Q9BYC5 | protein_coding | tolerated(0.08) | benign(0.12) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
FUT8 | SNV | Missense_Mutation | novel | c.601N>A | p.Pro201Thr | p.P201T | Q9BYC5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FUT8 | SNV | Missense_Mutation | novel | c.824N>C | p.Gly275Ala | p.G275A | Q9BYC5 | protein_coding | tolerated(1) | benign(0.271) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
FUT8 | insertion | Nonsense_Mutation | novel | c.1184_1185insATTCTAAGTGTTAGACGTAAAGAAGGTACATGTGAAGT | p.Arg396PhefsTer2 | p.R396Ffs*2 | Q9BYC5 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
FUT8 | SNV | Missense_Mutation | novel | c.643N>G | p.Asn215Asp | p.N215D | Q9BYC5 | protein_coding | deleterious(0.01) | possibly_damaging(0.812) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FUT8 | SNV | Missense_Mutation | novel | c.1097N>A | p.Arg366His | p.R366H | Q9BYC5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FUT8 | SNV | Missense_Mutation | novel | c.1673N>C | p.Val558Ala | p.V558A | Q9BYC5 | protein_coding | tolerated(0.2) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FUT8 | SNV | Missense_Mutation | | c.1033N>C | p.Glu345Gln | p.E345Q | Q9BYC5 | protein_coding | tolerated(0.32) | benign(0.307) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FUT8 | SNV | Missense_Mutation | rs765246656 | c.1720G>A | p.Glu574Lys | p.E574K | Q9BYC5 | protein_coding | tolerated(0.43) | benign(0.027) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FUT8 | insertion | Frame_Shift_Ins | novel | c.1200_1201insA | p.Arg403LysfsTer8 | p.R403Kfs*8 | Q9BYC5 | protein_coding | | | TCGA-IR-A3LC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | Complete Response |